Taysha Gene Therapies Q3 net loss widens as R&D costs rise

Reuters

Nov 04, 2025

<a href="https://laohu8.com/S/TSHA">Taysha Gene Therapies</a> Q3 net loss widens as R&D costs rise

Overview

Taysha reports bigger Q3 net loss of $32.7 mln, with increased R&D expenses
TSHA-102 granted FDA Breakthrough Therapy designation for Rett syndrome
Company regained full rights to TSHA-102 Rett syndrome program in October

Outlook

Company plans to dose first patient in REVEAL trial in Q4 2025
Taysha expects additional patient enrollment at multiple sites this quarter
Company regained full rights to TSHA-102 program for strategic flexibility

Result Drivers

Research and Development Expenses - R&D costs up to $25.7 mln from $14.9 mln

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.09
Q3 Net Income		-$32.73 mln
Q3 Operating Expenses		$34.02 mln
Q3 Operating Income		-$34.02 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $9.00, about 50.4% above its November 3 closing price of $4.46

Press Release: ID:nGNXcfDdHY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580736319"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580736319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580736319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580736319","market":"fut","top_or_hot":-1,"title":"Taysha Gene Therapies Q3 net loss widens as R&D costs rise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/TSHA\">Taysha Gene Therapies</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Taysha reports bigger Q3 net loss of $32.7 mln, with increased R&amp;D expenses</p></li><li><p>TSHA-102 granted FDA Breakthrough Therapy designation for Rett syndrome</p></li><li><p>Company regained full rights to TSHA-102 Rett syndrome program in October</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to dose first patient in REVEAL trial in Q4 2025</p></li><li><p>Taysha expects additional patient enrollment at multiple sites this quarter</p></li><li><p>Company regained full rights to TSHA-102 program for strategic flexibility</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>Research and Development Expenses - </span>R&amp;D costs up to $25.7 mln from $14.9 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$32.73 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$34.02 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$34.02 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $9.00, about 50.4% above its November 3 closing price of $4.46</p></li></ul><p>Press Release: <span>ID:nGNXcfDdHY</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taysha Gene Therapies Q3 net loss widens as R&D costs rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaysha Gene Therapies Q3 net loss widens as R&D costs rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/TSHA\">Taysha Gene Therapies</a> Q3 net loss widens as R&amp;D costs rise</title></head><body><p><span>Overview</span></p><ul><li><p>Taysha reports bigger Q3 net loss of $32.7 mln, with increased R&amp;D expenses</p></li><li><p>TSHA-102 granted FDA Breakthrough Therapy designation for Rett syndrome</p></li><li><p>Company regained full rights to TSHA-102 Rett syndrome program in October</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to dose first patient in REVEAL trial in Q4 2025</p></li><li><p>Taysha expects additional patient enrollment at multiple sites this quarter</p></li><li><p>Company regained full rights to TSHA-102 program for strategic flexibility</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>Research and Development Expenses - </span>R&amp;D costs up to $25.7 mln from $14.9 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.09</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$32.73 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$34.02 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$34.02 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $9.00, about 50.4% above its November 3 closing price of $4.46</p></li></ul><p>Press Release: <span>ID:nGNXcfDdHY</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSHA","symbol_name":"Taysha Gene Therapies, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0IQ:1","article_id":"2580736319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580736319","pubTimestamp":1762258586,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Taysha Gene Therapies Q3 net loss widens as R&D costs riseOverviewTaysha reports bigger Q3 net loss of $32.7 mln, with increased R&D expensesTSHA-102 granted FDA Breakthrough Therapy designation for R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TSHA":"Taysha Gene Therapies, Inc.","BK4139":"生物科技"},"translate_title":"随着研发成本上升，Taysha Gene Therapies第三季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSHA":0.9},"content_text":"Taysha Gene Therapies Q3 net loss widens as R&D costs riseOverviewTaysha reports bigger Q3 net loss of $32.7 mln, with increased R&D expensesTSHA-102 granted FDA Breakthrough Therapy designation for Rett syndromeCompany regained full rights to TSHA-102 Rett syndrome program in OctoberOutlookCompany plans to dose first patient in REVEAL trial in Q4 2025Taysha expects additional patient enrollment at multiple sites this quarterCompany regained full rights to TSHA-102 program for strategic flexibilityResult DriversResearch and Development Expenses - R&D costs up to $25.7 mln from $14.9 mlnKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.09Q3 Net Income-$32.73 mlnQ3 Operating Expenses$34.02 mlnQ3 Operating Income-$34.02 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 13 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $9.00, about 50.4% above its November 3 closing price of $4.46Press Release: ID:nGNXcfDdHYFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}